Kymera Therapeutics Inc
Closed
SectorHealthcare
117.35 3.11
Overview
Share price change
24h
Min
111.89
Max
117.97
Income | 8M -61M |
|---|---|
Sales | 31M 65M |
EPS | -0.62 |
Profit margin | -94.171 |
Employees | 273 |
EBITDA | 6M -61M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +14.78% upside |
Next Earnings | 3 lis 2026 |
|---|
Market Cap | 777M 9B |
|---|---|
Previous open | 114.24 |
Previous close | 117.35 |
Kymera Therapeutics Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Kymera Therapeutics Inc Forecast
Price Target
By TipRanks
14.78% upside
12 Months Forecast
Average 131.33 USD 14.78%
High 155 USD
Low 112 USD
Based on 18 Wall Street analysts offering 12 month price targets forKymera Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.